The effect of clotting factor concentrates on the immune system in HIV-negative haemophilics

Haemophilia

Volumn 11, Issue 4, 2005, Pages 366-370

  Balkan, Can ^a   Kavakli, K ^a   Kutukculer, N ^a   Aksu, G ^a   Yilmaz, D ^a   Aydinok, Y ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Factor concentrates; Haemophilia; Immune parameters

Indexed keywords

BCG VACCINE; BLOOD CLOTTING FACTOR CONCENTRATE; CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN G; TETANUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG PURITY; HEMOPHILIA; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ANTIBODY FORMATION; BCG VACCINE; BLOOD COAGULATION FACTORS; HEMOPHILIA A; HEMOPHILIA B; HIV SERONEGATIVITY; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LYMPHOCYTE COUNT; TETANUS; TUBERCULIN TEST;

EID: 22744447224     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01110.x     Document Type: Article

References (24)

1. Watson HG, Ludlam CA. Immunological abnormalities in hemophilia. Blood Rev 1992; 6: 26-33.
2. Berntorp E. Impact of replacement therapy on the evaluation of HIV infection in hemophiliacs. Thromb Haemost 1994; 71: 678-83.
3. Allersma DP, Smid WM, Brier E. Abnormal immune parameters in HIV-seronegative haemophilic patients. Haemophilia 1996; 2: 65-72.
4. Gomperts ED, de Biasi R, De Vreker R. The impact of clotting factor concentrates on the immune system in individuals with hemophilia. Transfus Med Rev 1992; 6: 44-54.
5. Allersma DP, Smid WM, van der Does JA, van der Meer J, Briet E. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryopresipitate and factor VIII concentrate. Thromb Haemost 1996; 75: 261-6.
6. Nilsson IM, Berntorp E, Löfquist T, Petterson H. Twenty five years experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992: 232: 25-32.
7. Evans JA, Pasi KJ, Williams MD, Hill FGH. Consistently normal CD4+, CD8+ levels in hemophilic boys only treated with vitally safe factor VIII concentrate (BPL 8Y). Br J Haematol 1991; 79: 457-61.
8. Watson HG, Goulden NJ, Ludlam CA. Oesophageal candidiasis in a HIV negative individual treated with factor VIII concentrate. Thromb Haemost 1992; 68: 782-6.
9. Beddall AC, Hill FG, George RH, Williams MD, al-Rubri K. Unusually high incidence of tuberculosis among boys with haemophilia during an outbreak of the disease in hospital. J Clin Pathol 1985; 38: 1163-5.
10. Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-β as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs. Blood 1994; 84: 2021-30.
11. Galazka MA. Tetanus. The immunological basis for immunization. Geneva: WHO/EPI, 1993; 1-13.
12. Schroder JP, Kahlmarin WD. Preventive tetanus immunization and avoidance of side effects of booster immunization. Dtsch Med Wochenschr 1992; 117: 1903-6.
13. Hoots K, Canty D. Clotting factor concentrates and immune function in haemophilic patients. Haemophilia 1998; 4: 704-13.
14. De la Barrera SS, Olabuenaga SE, Soria A, Felippo M, Bianco RP, de Bracco MME. HIV infection and natural killer cytotoxicity in hemophilic patients. Imm Letters 1990; 24: 207-16.
15. Kim Y, Yang CH, Kang SH, Kim DS. A comprehensive study of immunological abnormalities in Korean hemophiliacs. Yonsei Med J 1989; 30: 180-5.
16. Smid WM, van der Meer J, Smit JW, Halie MR. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated fort two years with a monoclonal purified factor concentrate. Thromb Haemost 1993; 69: 306-10.
17. Levine PH. Factor VIII:C purified from plasma via monoclonal antibodies: human studies. Semin Hematol 1988; 25 (Suppl. 1): 38-41.
18. Kehrl JH, Wakefield LM, Roberts AB et al. Production of transforming growth factor-β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986; 163: 1037-50.
19. Thorpe R, Dilger P, Dawson NJ, Barrowcliffe TW. Inhibition of interleukin-2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs. Br J Haematol 1989; 71: 387-91.
20. Pearson HJL, Stirling D, Ludlam CA, Steel CM. TGF-β is not the principal immunosuppressive component in coagulation factor concentrates. Br J Haematol 1999; 106: 971-9.
21. Cuthbert RJG, Ludlam CA, Steel CM, Beatson D, Peutherer JF. Immunological studies in HIV scronegative hemophiliacs: relationship to blood product therapy. Br J Haematol 1992; 80: 364-9.
22. Kavakli K, Nisli G, Kutukculer N et al. Long-term prophylaxis and immune parameters in haemophilia. J Trop Pediatr 1999; 45: 122-3.
23. Madhok R, Gracie JA, Smith J, Lowe GDO, Forbes CD. Capacity to produce interleukin 2 is impaired in haemophilia in the absence and presence of HIV 1 infection. Br J Haematol 1990; 76: 70-4.
24. Brettler DB, Forsberg AD, Brewster F, Sullivan JL, Levine PH. Delayed cutaneous hypersensitivity reactions in hemophilic subjects treated with factor concentrates. Am J Med 1986; 81: 607-11.